PMID- 27363700
OWN - NLM
STAT- MEDLINE
DCOM- 20170322
LR  - 20181113
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 23
IP  - 1
DP  - 2017 Jan
TI  - HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic 
      Disease.
PG  - 55-61
LID - 10.1007/s12253-016-0082-5 [doi]
AB  - HER2 (human epidermal growth factor receptor-2) assessment in histological 
      samples of gastric cancer is essential to determine which patients might benefit 
      from trastuzumab therapy. HER2 is often evaluated in primary tumor even if 
      trastuzumab therapy is used to treat metastatic disease. However, the exact 
      relationship in terms of HER2 status between primary and metastatic tumors has 
      not been fully clarified. We aimed to evaluate the HER2 status concordance 
      between primary gastric cancer and corresponding distant metastasis. HER2 status 
      was evaluated by IHC (immunohistochemistry) and/or FISH ( fluorescence in situ 
      hybridization) in 41 patients in primary gastric cancer and in paired metastasis. 
      HER2 was assessed according scoring criteria applied in clinical approach. HER2 
      positivity was found in 14,6 % primary tumors and in 24,4%corresponding 
      metastasis. HER2 concordance rate between primary and metastasis was 80,5 % 
      (K-value = 0,388). Eight/41 (19,5 %)cases resulted discordant: 6 patients with 
      metastatic HER2 positive lesions were found HER2 negative in primary cancers 
      while 2 patient HER2 positive in primary lesion showed a negative conversion in 
      metastasis. Our results showed a good concordance in terms of HER2 status between 
      primary and metastatic lesions, as well as in biopsy and surgical removed 
      specimens. However, the higher rate of HER2 positive status found in metastatic 
      lesions underlined the importance of HER2 assessment in all samples obtained from 
      different sites of gastric cancer disease.
FAU - Amato, Michelina
AU  - Amato M
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Perrone, Giuseppe
AU  - Perrone G
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy. g.perrone@unicampus.it.
FAU - Righi, Daniela
AU  - Righi D
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Pellegrini, Claudio
AU  - Pellegrini C
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Rabitti, Carla
AU  - Rabitti C
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Di Matteo, Francesco
AU  - Di Matteo F
AD  - Endoscopic Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 
      200, Rome, Italy.
FAU - Crucitti, Pierfilippo
AU  - Crucitti P
AD  - Department of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Caputo, Damiano
AU  - Caputo D
AD  - Department of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Coppola, Roberto
AU  - Coppola R
AD  - Department of Surgery, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
FAU - Tonini, Giuseppe
AU  - Tonini G
AD  - Oncology Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 
      200, Rome, Italy.
FAU - Santini, Daniele
AU  - Santini D
AD  - Oncology Unit, Campus Bio-Medico University of Rome, Via Alvaro del Portillo, 
      200, Rome, Italy.
FAU - Onetti Muda, Andrea
AU  - Onetti Muda A
AD  - Department of Pathology, Campus Bio-Medico University of Rome, Via Alvaro del 
      Portillo, 200, Rome, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20160630
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
CIN - Pathol Oncol Res. 2018 Jul;24(3):695-696. PMID: 28664475
MH  - Antineoplastic Agents/therapeutic use
MH  - Biopsy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/drug therapy/*genetics/pathology
MH  - Receptor, ErbB-2/*genetics
MH  - Stomach Neoplasms/drug therapy/*genetics/pathology
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - FISH
OT  - Gastric cancer
OT  - HER2
OT  - Immunoistochemistry
OT  - Metastatic disease
EDAT- 2016/07/02 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/07/02 06:00
PHST- 2016/01/04 00:00 [received]
PHST- 2016/06/14 00:00 [accepted]
PHST- 2016/07/02 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
PHST- 2016/07/02 06:00 [entrez]
AID - 10.1007/s12253-016-0082-5 [pii]
AID - 10.1007/s12253-016-0082-5 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2017 Jan;23(1):55-61. doi: 10.1007/s12253-016-0082-5. Epub 2016 
      Jun 30.